Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours

Next Previous
Trial Profile

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 225 Actinium FPI 1434 (Primary) ; FPI-1175 (Primary) ; FPI-1547 (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Cervical cancer; Endometrial cancer; Ewing's sarcoma; Head and neck cancer; HER2 negative breast cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Fusion Pharmaceuticals

Most Recent Events

  • 28 Nov 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
  • 04 Jan 2024 Results presented in a Fusion Pharmaceuticals media release.
  • 04 Jan 2024 According to a Fusion Pharmaceuticals media release, the company plans to complete and further evaluate results from Cohort 2 and hold a Safety Review Committee (SRC) meeting to evaluate the emerging data and plans to share more details on the data and the FPI-1434 development program in mid-2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top